Group 1 - The Federal Reserve has lowered interest rates by 25 basis points and indicated two more rate cuts this year, potentially initiating a rate-cutting cycle that may enhance global market liquidity [1] - The long development cycle and high costs associated with innovative drug research may benefit from lower financing costs due to the interest rate cuts, which could improve the performance of the innovative drug sector in the secondary market [1] - The recent fluctuations in the innovative drug sector, particularly in the Hong Kong market, have seen the Hang Seng Pharmaceutical ETF (159892) experience a two-day pullback, yet it has attracted significant capital with a total subscription amount exceeding 700 million yuan in the past five days, ranking it among the top in its category [1] Group 2 - According to Industrial Securities, China's innovative drugs possess advantages in high efficiency and low-cost development, particularly in popular technology areas such as ADC, bispecific antibodies, and cell therapy, which are expected to maintain competitive strength in the industry [1]
创新药震荡调整，资金跑步进场，恒生医药ETF连续5日获资金申购
Sou Hu Cai Jing·2025-09-18 01:19